New Research Grants Fund PAT-DX1 and PAT-DX1-NP Targeting Brain Tumors

Patrys is a publicly-listed company company focused on developing novel antibody technologies for hard-to-treat cancers.

Get news and updates from Patrys delivered to your inbox.

Keep up to date with the latest news from Patrys by following us on social media.

Menu